Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

9.140
-0.110-1.19%
Volume:2.34M
Turnover:21.35M
Market Cap:8.81B
PE:-27.84
High:9.320
Open:9.280
Low:8.900
Close:9.250
Loading ...

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule ThrΒ Agonist, Asc47, and Semaglutide for the Treatment of Obesity

THOMSON REUTERS
·
Yesterday

Ascletis Pharma Completes Dosing in U.S. Clinical Trial for Obesity Treatment Combining ASC47 and Semaglutide

Reuters
·
Yesterday

This Ascletis Pharma Insider Increased Their Holding In The Last Year

Simply Wall St.
·
14 Jul

HK Movers | Pharma Stocks Shine. Luye Pharma up 8%; Hua Medicine, Hengrui Pharma up 7%; Sino Biopharm, Fudan Zhangjiang up over 3%

Tiger Newspress
·
09 Jul

HK Movers|Biotech Stocks Gained. RemeGen, Junshi Bio And TigerMed Up 3%; Laekna And JW Therap Up 1%

Tiger Newspress
·
08 Jul

HK Movers|HK Innovative Drug Concept Stocks Rose. Biostar Up 15%; Akeso Up 11%; SKB Bio And Innovent Bio Up More Than 7%

Tiger Newspress
·
03 Jul

Ascletis Announces First Participants With Obesity or Overweight Dosed in a U.S. 13-Week Phase Iia Study of Small Molecule Oral Glp-1R Agonist Asc30

THOMSON REUTERS
·
03 Jul

Ascletis Pharma Inc. Announces Dosing of First Participants in U.S. Phase IIa Study of Oral GLP-1R Agonist ASC30 for Obesity Treatment

Reuters
·
03 Jul

Ascletis Pharma Faces Third-Party Challenge Over U.S. Patent Validity in Post Grant Review

Reuters
·
30 Jun

Ascletis Pharma Inc - Third-Party Petition Filed Against Company's U.S. Patent

THOMSON REUTERS
·
30 Jun

Ascletis Pharma Inc - Petition Remains Under Review by Uspto as at June 30

THOMSON REUTERS
·
30 Jun

Ascletis Pharma - Petition Challenged Validity of Claims of Granted U.S. Patent No. 12,234,236 Owned by Ascletis Pharma (China) Co

THOMSON REUTERS
·
30 Jun

Ascletis Pharma Inc - Become Aware of Petition for Post Grant Review Filed With United States Patent and Trademark Office by Conjupro Biotherapeutics

THOMSON REUTERS
·
30 Jun

Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of Asc50, a Potential Best-in-Class Oral Small Molecule Il-17 Inhibitor for the Treatment of Psoriasis

THOMSON REUTERS
·
18 Jun

Ascletis Pharma Inc. Announces First Participants Dosed in U.S. Phase I Clinical Trial of Potential Best-in-Class Psoriasis Treatment ASC50

Reuters
·
18 Jun

HK Movers | HK's Biotech Shares Soar. JOINN Soars 8%; Fudan-Zhangjiang up 6%; HeartCare up 2%

Tiger Newspress
·
17 Jun

HK Movers | Biotech Stocks Jump. Canbridge Soars 40%; Ascletis Jumps 17%; TYK Medicines Gains 7%; HBM Holdings, Abbisko Up More Than 6%

Tiger Newspress
·
16 Jun

China's Biotech Moment Ignites a 60% Stock Rally That Beats AI

Bloomberg
·
15 Jun

HK Movers|Pharma Shares Rallied. Sino Biopharm Up 13%; Immunothech And Zai Lab Up 5%; Dualitybio And Grand Pharmaup 4%

Tiger Newspress
·
12 Jun

Ascletis Announces Poster Presentations on the Study Results of Asc30 and Asc47 at the 85TH Scientific Sessions of American Diabetes Association (Ada)

THOMSON REUTERS
·
09 Jun